ISSN : 0970 - 020X, ONLINE ISSN : 2231-5039
     FacebookTwitterLinkedinMendeley

Synthesis, Characterization and Biological Evaluation of Some Novel Thiophene Anchored Fluorinated Heterocycles

B. K. Karale1*, H. N. Akolkar1, A. S. Burungale2, S. D. Mhaske1 and R. S. Endait1  

1P. G. Department of Chemistry, Radhabai Kale Mahila Mahavidyalaya, Ahmednagar, 414001, India.

2Post-Graduate and Research Center in Chemistry, S. M. Joshi College, Hadapsar, Pune-28

DOI : http://dx.doi.org/10.13005/ojc/310155

Article Publishing History
Article Received on :
Article Accepted on :
Article Published : 08 Feb 2015
Article Metrics
ABSTRACT:

A new series of thiophene anchored 1,3,4-thiadiazole, 1,2,4-triazole, 2-heteryl chromone, 1,5-benzothiazepine, pyrazoline, 2-styryl chromone derivatives containing fluorine are synthesized, characterized by spectral methods and screened them for various biological activities.

KEYWORDS:

1;3;4-Thiadiazole; 1;2;4-Triazole; 2-Heteryl chromone; 1;5-Benzothiazepine; Pyrazoline; 2-Styryl chromone

Download this article as: 

Copy the following to cite this article:

Karale B. K, Akolkar H. N, Burungale A. S, Mhaske S. D, Endait R. S. Synthesis, Characterization and Biological Evaluation of Some Novel Thiophene Anchored Fluorinated Heterocycles. Orient J Chem 2015;31(1).


Copy the following to cite this URL:

Karale B. K, Akolkar H. N, Burungale A. S, Mhaske S. D, Endait R. S. Synthesis, Characterization and Biological Evaluation of Some Novel Thiophene Anchored Fluorinated Heterocycles. Orient J Chem 2015;31(1). Available from: http://www.orientjchem.org/?p=7060


Introduction

Thiophene is sulfur containing five membered heterocyclic compound widely used as building block in agrochemicals1. Thiophene containing compounds exhibit antimicrobial2, antiparasitic3, anticancer4 and anticonvulsant 5 activities.

2-Styryl chromones are associated with various pharmacological activities such as antiallergic6, cytotoxic7, antioxidant8, anti-inflammatory9 and antibacterial10. 2-Styryl chromones are also acts as β-amyloid imaging agents11. Pyrazole derivatives are known for various potent biological activities such as antibacterial12, antioxidant12, anticancer13, ACE inhibitor14.

 

Scheme 1 Scheme 1 

Click here to View scheme

 

Thiadiazole derivatives possess antitumor15, antiinflammatory16, SIRT1 inhibitor17, antihypertensive18, antimicrobial19 activities. 1,2,4-Triazole anchored compounds are associated with antimicrobial19, antioxidant20, anti-inflammatory20, CYP enzyme inhibitor21, anxiolytic22 activities.

Compounds containing chromone scaffold are acts as breast cancer resistance protein ABCG2 inhibitor23, monoamine oxidase inhibitor24, adenosine A2A receptor antagonists25. Some 1,5-benzothiazepines are antifungal26, anticonvulsant27, anti breast cancer28, antithrombotic29, antidepressant30 agents. Compounds having pyrazoline moity are known to possess anti-inflammatory31, antimalarial32, antitubercular33, antidepressant34 activities.

The activities associated with these various heterocycles prompted us to synthesize some novel thiophene anchored fluorinated heterocycles.

Scheme 2 Scheme 2

Click here to View scheme

 

Biological Activities

Antimicrobial activity

Synthesized compounds were screened for their antifungal and antibacterial activities. The in vitro antimicrobial activities of the synthesized compounds were assessed against fungi and bacteria. The fungi used were C. albicans, A. Fumigatus and A. Niger. The bacterias used were S. aureus, E. coli, S. Epidermidis and P. Vulgaris.

Scheme 1 Scheme 3 

Click here to View scheme

 

Fluconazole and Amikacin were used as standards for comparison for antifungal and antibacterial activities respectively. The activities were determined by measuring the diameter of the inhibition zone in mm.

None of the compounds is a suitable candidate for antifungal and antibacterial indication as shown in Table 2.

Experimental

Melting points were recorded in open capillaries in liquid paraffin bath and are uncorrected. IR spectra were recorded on Perkin-Elmer FTIR spectrophotometer in KBr disc.1H NMR spectra were recorded on Bruker 400 MHz NMR spectrometer in DMSO as a solvent and TMS as an internal standard. Peak values are shown in δ (ppm). Mass spectra were recorded on Finnigan mass spectrometer.

2-{[4-Bromo-5-(methylsulfanyl)thiophen-2-yl]carbonyl}-N-phenylhydrazinecarbothioamide 2.

Equimolar amounts (0.01 mole) of compound 1 and aryl isothiocyanate were dissolved in 15 mL of ethanol. The reaction mixture was heated under reflux for 55 minutes. The progress of reaction was monitored by TLC. After completion of reaction the contents were cooled and the solid obtained was filtered and crystallized from ethanol to get compound 2.

2a

IR (KBr, cm-1): 3327, 3228, 3113, 1643, 1257; 1H NMR (DMSO): δ 2.22 (s, 3H), 3.3 (s, 3H), 7.00-7.20 (m, 4H), 7.8 (s, 1H), 9.5 (s, 2H), 10.6 (s, 1H); MS: m/z 430 (M+); Elemental Anal. Calcd.: C, 38.89; H, 3.26; N, 9.72; found: C, 38.91; H, 3.29; N, 9.74 %.

2b

IR (KBr, cm-1): 3324, 3220, 3117, 1640, 1262; 1H NMR (DMSO): δ 2.21 (s, 3H), 7.04-7.21 (m, 4H), 7.87 (s, 1H), 9.54 (s, 2H), 10.64 (s, 1H); MS: m/z 418 (M+); Elemental Anal. Calcd.: C, 37.15; H, 2.64; N, 10.00; found: C, 37.18; H, 2.67; N, 10.04 %.

2c

IR (KBr, cm-1): 3330, 3224, 3109, 1647, 1255; 1H NMR (DMSO): δ 2.21 (s, 3H), 7.03-7.20 (m, 4H), 7.86 (s, 1H), 9.53 (s, 2H), 10.62 (s, 1H); MS: m/z 434 (M+); Elemental Anal. Calcd.: C, 35.75; H, 2.54; N, 9.62; found: C, 35.78; H, 2.57; N, 9.65 %.

2d

IR (KBr, cm-1): 3328, 3225, 3111, 1641, 1257; 1H NMR (DMSO): δ 2.22 (s, 3H), 7.00-7.25 (m, 5H), 7.83 (s, 1H), 9.52 (s, 2H), 10.65 (s, 1H); MS: m/z 400 (M+); Elemental Anal. Calcd.: C, 38.81; H, 3.01; N, 10.44; found: C, 38.84; H, 3.05; N, 10.48 %.

2e

IR (KBr, cm-1): 3330, 3224, 3119, 1651, 1264; 1H NMR (DMSO): δ 2.20 (s, 3H), 3.34 (s, 3H), 7.05-7.24 (m, 4H), 7.81 (s, 1H), 9.53 (s, 2H), 11.01 (s, 1H); MS: m/z 430 (M+); Elemental Anal. Calcd.: C, 38.89; H, 3.26; N, 9.72; found: C, 38.92; H, 3.29; N, 9.74 %.

5-(4-Bromo-5-(methylthio)thiophen-2-yl)-N-phenyl-1,3,4-thiadiazol-2-amine 3

Thiosemicarbazide 2 (0.001 mole) was dissolved in 3 mL of conc. H2SO4 in 50 mL beaker. The reaction mixture was stirred at room temperature for 3 hr. After completion of reaction 10 g of crushed ice was added in it. The solid obtained was separated by filtration and crystallized from 1:1 mixture of DMF and water to afford thiadiazole 3.

3a

IR (KBr, cm-1): 3161, 1633, 1591; 1H NMR (DMSO): δ  2.3 (s, 3H), 3.5 (s, 3H), 6.9-7.4 (m, 4H), 7.8 (s, 1H), 10.9 (s, 1H); MS: m/z 412 (M+); Anal. Calcd.: C, 40.58; H, 2.92; N, 10.14; found: C, 40.60; H, 2.94; N, 10.17 %.

3b

IR (KBr, cm-1): 3166, 1630, 1587; 1H NMR (DMSO): δ  2.31 (s, 3H), 6.95-7.82 (m, 5H), 10.94 (s, 1H); MS: m/z 400 (M+); Anal. Calcd.: C, 38.81; H, 2.25; N, 10.44; found: C, 38.84; H, 2.28; N, 10.47 %.

3c

IR (KBr, cm-1): 3156, 1638, 1598; 1H NMR (DMSO): δ  2.30 (s, 3H), 6.91-7.83 (m, 5H), 10.91 (s, 1H); MS: m/z 416 (M+); Anal. Calcd.: C, 37.28; H, 2.17; N, 10.03; found: C, 37.31; H, 2.20; N, 10.06 %.

3d

IR (KBr, cm-1): 3167, 1632, 1588; 1H NMR (DMSO): δ  2.31 (s, 3H), 6.92-7.89 (m, 6H), 10.93 (s, 1H); MS: m/z 382 (M+); Anal. Calcd.: C, 40.63; H, 2.62; N, 10.93; found: C, 40.66; H, 2.65; N, 10.96 %.

3e

IR (KBr, cm-1: 3164, 1629, 1592; 1H NMR (DMSO): δ  2.3 (s, 3H), 3.52 (s, 3H), 6.91-7.86 (m, 4H), 10.9 (s, 1H); MS: m/z 412 (M+); Anal. Calcd.: C, 40.58; H, 2.92; N, 10.14; found: C, 40.61; H, 2.95; N, 10.17 %.

5-(4-Bromo-5-(methylthio)thiophen-2-yl)-4-phenyl-4H-1,2,4-triazole-3-thiol 4.

A mixture of thiosemicarbazide 2 and 10 mL of 1N NaOH was heated under mild reflux for 1.5 hr. The progress of reaction was monitored by TLC. After completion of reaction the contents were cooled and poured into crushed ice. Then it was acidified with glacial acetic acid. The product was separated by filtration and crystallized from the mixture (1:1) of DMF and water to get corresponding triazole 4.

4a

IR (KBr, cm-1): 3070, 2997, 1583, 1517; 1H NMR (DMSO): δ 2.0 (s, 3H), 3.5 (s, 3H), 6.4-7.5 (m, 5H), 14.11 (s, 1H); MS: m/z 412 (M+); Anal. Calcd.: C, 40.58; H, 2.92; N, 10.14; found: C, 40.61; H, 2.95; N, 10.17 %.

4b

IR (KBr, cm-1): 3077, 2990, 1578, 1514; 1H NMR (DMSO): δ 2.01 (s, 3H), 6.49-7.56 (m, 5H), 14.12 (s, 1H); MS: m/z 400 (M+); Anal. Calcd.: C, 38.81; H, 2.25; N, 10.44; found: C, 38.84; H, 2.28; N, 10.47 %.

4c

IR (KBr, cm-1): 3081, 2983, 1588, 1521; 1H NMR (DMSO): δ 2.01 (s, 3H), 6.48-7.58 (m, 5H), 14.11 (s, 1H); MS: m/z 416 (M+); Anal. Calcd.: C, 37.28; H, 2.17; N, 10.03; found: C, 37.32; H, 2.20; N, 10.07; %.

4d: IR (KBr, cm-1): 3085, 2990, 1580, 1517; 1H NMR (DMSO): δ 2.01 (s, 3H), 6.4-7.57 (m, 6H), 14.1 (s, 1H); MS: m/z 382 (M+); Anal. Calcd.: C, 40.63; H, 2.62; N, 10.93; found: C, 40.67; H, 2.65; N, 10.96 %.

4e

IR (KBr, cm-1): 3074, 2991, 1589, 1510; 1H NMR (DMSO): δ 2.02 (s, 3H), 3.55 (s, 3H), 6.46-7.59 (m, 5H), 14.10 (s, 1H); MS: m/z 412 (M+); Anal. Calcd.: C, 40.58; H, 2.92; N, 10.14; found: C, 40.62; H, 2.95; N, 10.18;%.

 (E)-3-(1-(4-Fluorophenyl)-3-(thiophen-2-yl)-1H-pyrazol-4-yl)-1-(2-hydroxyphenyl)prop-2-en-1-one 10.

Equimolar amount of compound 8 (0.02 mole) and substituted o-hydroxy acetophenone (0.02 mole) were dissolved in 25 mL of alcohol in conical flask. To this reaction mixture 40% KOH (10mL) was added. The reaction mixture was stirred at room temperature for 48 hrs. The contents were then poured into crushed ice and neutralized with acetic acid. The yellow solid thus obtained was filtered and crystallized from alcohol to afford compound 10.

10a

IR (KBr, cm-1): 3134 (O-H), 1637 (C=O), 1568 (C=N), 1556 (-C=C-), 1508 (-C=C-, aromatic), 1155 (Ar-F); 1H NMR (DMSO- d6): d 7.26- 8.22 (m, 11H, Ar-H and =CH), 9.44 (s, 1H), 13.2 (s, 1H, -O-H); MS: m/z 458 (M+);; Anal. Calcd.: C, 57.53; H, 2.85; N, 6.10; found: C, 57.56; H, 2.88; N, 6.13 %.

10b

IR (KBr, cm-1): 3132 (O-H), 1633 (C=O), 1566 (C=N), 1549 (-C=C-), 1511 (-C=C-, aromatic), 1158 (Ar-F); 1H NMR (DMSO- d6): d 7.25- 8.34 (m, 12H, Ar-H and =CH), 9.47 (s, 1H), 13.21 (s, 1H, -O-H); MS: m/z 424 (M+); Anal. Calcd.: C, 62.19; H, 3.32; N, 6.59; found: C, 62.21; H, 3.35; N, 6.62%.

10c

IR (KBr, cm-1): 3129 (O-H), 1631 (C=O), 1569 (C=N), 1556 (-C=C-), 1510 (-C=C-, aromatic), 1157 (Ar-F); 1H NMR (DMSO- d6): d 7.27- 8.24 (m, 12H, Ar-H and =CH), 9.45 (s, 1H), 13.22 (s, 1H, -O-H); MS: m/z 468 (M+); Anal. Calcd.: C, 56.30; H, 3.01; N, 5.97; found: C, 56.34; H, 3.05; N, 6.01 %.

10d

IR (KBr, cm-1): 3130 (O-H), 1637 (C=O), 1571 (C=N), 1551 (-C=C-), 1501 (-C=C-, aromatic), 1149 (Ar-F); 1H NMR (DMSO- d6): d 2.2 (s, 3H), 7.25- 8.22 (m, 11H, Ar-H and =CH), 9.46 (s, 1H), 13.20 (s, 1H, -O-H); MS: m/z 438 (M+); Anal. Calcd.: C, 62.94; H, 3.67; N, 6.38; found: C, 62.98; H, 3.70; N, 6.41 %.

10e

IR (KBr, cm-1): 3134 (O-H), 1641 (C=O), 1561 (C=N), 1555 (-C=C-), 1509 (-C=C-, aromatic), 1155 (Ar-F); 1H NMR (DMSO- d6): d 2.24 (s, 3H), 2.29 (s, 3H),  7.27- 8.23 (m, 11H, Ar-H and =CH), 9.44 (s, 1H), 13.2 (s, 1H, -O-H); MS: m/z 418 (M+); Anal. Calcd.: C, 68.88; H, 4.58;  N, 6.69; found: C, 68.92; H, 4.62;  N, 6.73 %.

10f

IR (KBr, cm-1): 3140 (O-H), 1635 (C=O), 1567 (C=N), 1547 (-C=C-), 1499 (-C=C-, aromatic), 1146 (Ar-F); 1H NMR (DMSO- d6): d 2.24 (s, 3H), 7.21- 8.26 (m, 12H, Ar-H and =CH), 9.45 (s, 1H), 13.20 (s, 1H, -O-H); MS: m/z 404 (M+); Anal. Calcd.: C, 68.30; H, 4.24; N, 6.93; found: C, 68.34; H, 4.28; N, 6.97%.

2-(1-(4-Fluorophenyl)-3-(thiophen-2-yl)-1H-pyrazol-4-yl)-4H-chromen-4-one 11.

Compound 10 (0.001 mole) was dissolved in 15 ml DMSO. To this reaction mixture catalytic amount of iodine (0.01 gm) was added. The reaction mixture was heated to 100 to 1100C for 1.5 hrs and left overnight. Then 100 ml ice cold water was added in it. The solid thus obtained was filtered and washed with dil. sodium thiosulphate followed by water. The product was crystallized from alcohol to afford compounds 11.

11a

IR (KBr, cm-1): 1655 (C=O), 1567 (C=N), 1513 (C=C), 1158 (Ar-F), 1H NMR (DMSO- d6): d  6.77 (s, 1H, Ar-H), 7.14-8.16 (m, 9H, Ar-H), 9.22 (s, 1H); MS: m/z 456 (M+); Anal. Calcd.: C, 57.78; H, 2.42; N, 6.13; found: C, 57.82; H, 2.46; N, 6.17 %.

11b

IR (KBr, cm-1): 1649 (C=O), 1561 (C=N), 1508 (C=C), 1156 (Ar-F), 1H NMR (DMSO- d6): d  6.71 (s, 1H, Ar-H), 7.13-8.18 (m, 10H, Ar-H), 9.24 (s, 1H); MS: m/z 422 (M+); Anal. Calcd.: C, 62.49; H, 2.86; N, 6.62; found: C, 62.53; H, 2.89; N, 6.65%.

11c

IR (KBr, cm-1): 1651 (C=O), 1562 (C=N), 1516 (C=C), 1149 (Ar-F), 1H NMR (DMSO- d6): d  6.73 (s, 1H, Ar-H), 7.15-8.13 (m, 10H, Ar-H), 9.23 (s, 1H); MS: m/z 466 (M+); Anal. Calcd.: C, 56.54; H, 2.59; N, 5.99; found: C, 56.57; H, 2.62; N, 6.02 %.

11d

IR (KBr, cm-1): 1659 (C=O), 1571 (C=N), 1510 (C=C), 1148 (Ar-F), 1H NMR (DMSO- d6): d  6.77 (s, 1H, Ar-H), 7.15-8.19 (m, 9H, Ar-H), 9.23 (s, 1H); MS: m/z 436 (M+); Anal. Calcd.: C, 63.23; H, 3.23; N, 6.41; found: C, 63.27; H, 3.27; N, 6.45%.

11e

IR (KBr, cm-1): 1645 (C=O), 1569 (C=N), 1513 (C=C), 1155 (Ar-F), 1H NMR (DMSO- d6): d  2.23 (s, 3H), 2.29 (s, 3H), 6.79 (s, 1H, Ar-H), 7.13-8.15 (m, 9H, Ar-H), 9.21 (s, 1H); MS: m/z 416 (M+); Anal. Calcd.: C, 69.21; H, 4.11; N, 6.73; found: C, 69.25; H, 4.14; N, 6.76 %.

11f

IR (KBr, cm-1): 1650 (C=O), 1562 (C=N), 1507 (C=C), 1146 (Ar-F), 1H NMR (DMSO- d6): d  2.23 (s, 3H), 6.78 (s, 1H, Ar-H), 7.14-8.17 (m, 10H, Ar-H), 9.23 (s, 1H); MS: m/z 402 (M+); Anal. Calcd.: C, 68.64; H, 3.76; N, 6.96; found: C, 68.68; H, 3.79; N, 6.99 %.

2-(5-(1-(4-Fluorophenyl)-3-(thiophen-2-yl)-1H-pyrazol-4-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenol 12.

Compound 10 (0.003 mol) was taken in 100 mL RBF with 15 mL dioxane. To this reaction mixture 1 mL hydrazine hydrate was added and the contents were heated under refluxed for 4 hours. Then to the reaction mixture 2 mL gl. acetic acid was and heating was continued for further 3 hours. After complete heating contents were cooled to room temperature and poured over crushed ice. The solid thus obtained was separated by filtration and crystallized with alcohol to get compounds 12. Products obtained were identified with help of spectral data. Their characterization data is given in the Table-1.

Table 1 – Characterization data of synthesized compounds

Compd R1 R2 R3 m.p.(0C) Yield               (%) Compd R1 R2 R3 m.p.(0C) Yield               (%)
2a H OCH3 H 186 65 12a Cl H Cl 190 67
2b H H F 180 74 12b H H Cl 171 63
2c H H Cl 184 71 12c H H Br 194 70
2d H H H 179 73 12d H CH3 Cl 178 69
2e OCH3 H H 155 61 12e CH3 H CH3 156 62
3a H OCH3 H 180 60 12f H CH3 H 130 59
3b H H F 199 65 13a Cl H Cl 230 73
3c H H Cl 172 73 13b H H Cl 188 78
3d H H H 177 60 13c H H Br 200 74
3e OCH3 H H 190 62 13d H CH3 Cl 208 71
4a H OCH3 H 235 68 13e CH3 H CH3 232 69
4b H H F 209 72 13f H CH3 H 164 64
4c H H Cl 222 56 15a Cl H Cl 178 62
4d H H H 240 60 15b H H Cl 154 67
4e OCH3 H H 200 66 15c H H Br 168 66
10a Cl H Cl 218 72 15d H CH3 Cl 160 61
10b H H Cl 186 69 15e H H CH3 142 58
10c H H Br 178 66 16a Cl H Cl 250 69
10d H CH3 Cl 158 69 16b H H Cl 270 63
10e CH3 H CH3 160 68 16c H H Br 274 68
10f H CH3 H 160 63 16d H CH3 Cl 234 60
11a Cl H Cl 258 62 16e H H CH3 165 52
11b H H Cl 264 68 17a Cl H Cl 275 62
11c H H Br 254 67 17b H H Cl 295 65
11d H CH3 Cl 258 69 17c H H Br 284 60
11e CH3 H CH3 238 65 17d H CH3 Cl 298 63
11f H CH3 H 196 61 17e H H CH3 272 61

 

12a

IR (KBr, cm-1): 3405 (-O-H), 3320 (-N-H), 3071 (Ar-H), 1587 (C=N); 1H NMR (DMSO): δ 3.20 (dd, 1H), 3.74 (dd, 1H), 5.1 (t, 1H), 7.17-8.13 (m, 10H, aromatic and N-H protons), 8.58 (s, 1H, pyrazole proton), 12.00 (s, 1H, -O-H proton); MS: m/z 472 (M+); Anal. Calcd.: C, 55.82; H, 3.19; N, 11.84; found: C, 55.86; H, 3.23; N, 11.88 %.

12b

IR (KBr, cm-1): 3409 (-O-H), 3325 (-N-H), 3074 (Ar-H), 1580 (C=N); 1H NMR (DMSO): δ 3.21 (dd, 1H), 3.74 (dd, 1H), 5.11 (t, 1H), 7.16-8.14 (m, 11H, aromatic and N-H protons), 8.57 (s, 1H, pyrazole proton), 12.01 (s, 1H, -O-H proton); MS: m/z 438 (M+); Anal. Calcd.: C, 60.20; H, 3.67; N, 12.77; found: C, 60.24; H, 3.71; N, 12.80 %.

12c

IR (KBr, cm-1): 3402 (-O-H), 3322 (-N-H), 3070 (Ar-H), 1581 (C=N); 1H NMR (DMSO): δ 3.22 (dd, 1H), 3.74 (dd, 1H), 5.12 (t, 1H), 7.11-8.12 (m, 11H, aromatic and N-H protons), 8.59 (s, 1H, pyrazole proton), 12.04 (s, 1H, -O-H proton); MS: m/z 482 (M+); Anal. Calcd.: C, 54.67; H, 3.34; N, 11.59; found: C, 54.71; H, 3.38; N, 11.63 %.

12d

IR (KBr, cm-1): 3410 (-O-H), 3320 (-N-H), 3072 (Ar-H), 1577 (C=N); 1H NMR (DMSO): δ 2.23 (s, 3H), 3.21 (dd, 1H), 3.72 (dd, 1H), 5.11 (t, 1H), 7.16-8.16 (m, 10H, aromatic and N-H protons), 8.57 (s, 1H, pyrazole proton), 12.02 (s, 1H, -O-H proton); MS: m/z 452 (M+); Anal. Calcd.: C, 60.99; H, 4.01; N, 12.37; found: C, 61.03; H, 4.05; N, 12.41 %.

12e

IR (KBr, cm-1): 3407 (-O-H), 3324 (-N-H), 3065 (Ar-H), 1579 (C=N); 1H NMR (DMSO): δ 2.23 (s, 3H), 2.25 (s, 3H), 3.23 (dd, 1H), 3.73 (dd, 1H), 5.12 (t, 1H), 7.16-8.14 (m, 10H, aromatic and N-H protons), 8.56 (s, 1H, pyrazole proton), 12.01 (s, 1H, -O-H proton); MS: m/z 432 (M+); Anal. Calcd.: C, 66.65; H, 4.89; N, 12.95; found: C, 66.69; H, 4.93; N, 12.99 %.

12f

IR (KBr, cm-1): 3401 (-O-H), 3325 (-N-H), 3066 (Ar-H), 1591 (C=N); 1H NMR (DMSO): δ 2.24 (s, 3H), 3.21 (dd, 1H), 3.72 (dd, 1H), 5.13 (t, 1H), 7.15-8.13 (m, 11H, aromatic and N-H protons), 8.55 (s, 1H, pyrazole proton), 12.00 (s, 1H, -O-H proton); MS: m/z  418 (M+); Anal. Calcd.: C, 66.01; H, 4.58; N, 13.39; found: C, 66.05; H, 4.62; N, 13.43 %.

2-((E)-2-(1-(4-Fluorophenyl)-3-(thiophen-2-yl)-1H-pyrazol-4-yl)-2,3-dihydrobenzo[b][1,4]thiazepin-4-yl)phenol 13.

Compound 10 (0.001 mol) and o-amino thiophenol (0.001 mol) was suspended in 10 ml ethanol. Reaction mass was heated to reflux at 900C for 4-5h. To the reaction mixture 2 ml glacial acetic acid was added and heating continued for further 3h. Contents were cooled and poured into crushed ice. The product obtained was separated by filtration and crystallized from ethanol. Products obtained were identified with help of spectral data. Their characterization data is given in the Table-1.

13a: IR (KBr): 3413 (-O-H),  3066 (Ar-H), 1590 & 1566 (C=N), 612 (C-S) cm-1; 1H NMR (DMSO): δ 3.12 (t, 1H), 3.76 (dd, 1H), 5.57 (dd, 1H), 7.18-8.05 (m, 13H, Ar-H), 8.51 (s, 1H, pyrazole proton), 15.9 (s, 1H, -O-H proton); MS: m/z 565 (M+); Anal. Calcd.: C, 59.36; H, 3.20; N, 7.42; found: C, 59.40; H, 3.23; N, 7.46;%.

13b: IR (KBr): 3411 (-O-H),  3070 (Ar-H), 1594 & 1570 (C=N), 611 (C-S) cm-1; 1H NMR (DMSO): δ 3.11 (t, 1H), 3.75 (dd, 1H), 5.57 (dd, 1H), 7.17-8.04 (m, 14H, Ar-H), 8.50 (s, 1H, pyrazole proton), 15.95 (s, 1H, -O-H proton); MS: m/z 531 (M+); Anal. Calcd.: C, 63.21; H, 3.60; N, 7.90; found: C, 63.25; H, 3.64; N, 7.94 %.

13c: IR (KBr): 3409 (-O-H),  3062 (Ar-H), 1597 & 1562 (C=N), 616 (C-S) cm-1; 1H NMR (DMSO): δ 3.12 (t, 1H), 3.77 (dd, 1H), 5.54 (dd, 1H), 7.16-8.07 (m, 14H, Ar-H), 8.52 (s, 1H, pyrazole proton), 15.93 (s, 1H, -O-H proton); MS: m/z 575 (M+); Anal. Calcd.: C, 58.33; H, 3.32; N, 7.29; found: C, 58.37; H, 3.36; N, 7.33 %.

13d: IR (KBr): 3407 (-O-H),  3068 (Ar-H), 1590 & 1568 (C=N), 611 (C-S) cm-1; 1H NMR (DMSO): δ 2.24 (s, 3H), 3.10 (t, 1H), 3.73 (dd, 1H), 5.57 (dd, 1H), 7.17-8.07 (m, 13H, Ar-H), 8.50 (s, 1H, pyrazole proton), 15.92 (s, 1H, -O-H proton); MS: m/z 545 (M+); Anal. Calcd.: C, 63.78; H, 3.88; N, 7.69; found: C, 63.82; H, 3.92; N, 7.73 %.

13e: IR (KBr): 3410 (-O-H),  3066 (Ar-H), 1594 & 1565 (C=N), 610 (C-S) cm-1; 1H NMR (DMSO): δ 2.24 (s, 3H), 2.26 (s, 3H), 3.13 (t, 1H), 3.74 (dd, 1H), 5.56 (dd, 1H), 7.16-8.01 (m, 13H, Ar-H), 8.53 (s, 1H, pyrazole proton), 15.91 (s, 1H, -O-H proton); MS: m/z 525 (M+); Anal. Calcd.: C, 68.55; H, 4.60; N, 7.99; found: C, 68.59; H, 4.64; N, 8.03 %.

13f: IR (KBr): 3404 (-O-H),  3062 (Ar-H), 1584 & 1559 (C=N), 610 (C-S) cm-1; 1H NMR (DMSO): δ 2.21 (s, 3H), 3.12 (t, 1H), 3.74 (dd, 1H), 5.57 (dd, 1H), 7.14-8.03 (m, 14H, Ar-H), 8.54 (s, 1H, pyrazole proton), 15.90 (s, 1H, -O-H proton); MS: m/z 511 (M+); Anal. Calcd.: C, 68.08; H, 4.33; N, 8.21; found: C, 68.11; H, 4.37; N, 8.24 %.

(E)-2-Acetylphenyl 3-(1-(4-fluorophenyl)-3-(thiophen-2-yl)-1H-pyrazol-4-yl)acrylate 15.

Equimolar amount (0.05 moles) of the compounds 14 and substituted 2-hydroxy acetophenone were taken in dry beaker. To this mixture was dissolved in 15 ml dry pyridine. The reaction mixture was then cooled to 00C. To this reaction mixture POCl3 (0.06 moles) was added drop wise maintaining temperature below 100C. Then reaction mixture was kept overnight at room temperature. It was then poured over crushed ice with vigorous stirring. Product was separated by filtration, washed with ice-cold water and then with 2% ice-cold solution of NaOH followed by ice-cold water again. Purification by crystallization after drying with alcohol afforded 15.

15a

IR (KBr, cm-1): 3120 (O-H), 1736 (C=O), 1549 (C=N), 1545 (-C=C-), 1499 (-C=C-, aromatic), 1147 (Ar-F); 1H NMR (DMSO- d6): d 2.21 (s, 3H), 7.05- 8.30 (m, 11H, Ar-H and =CH), 8.44 (s, 1H, pyrazole proton);  MS: m/z 500 (M+); Anal. Calcd.: C, 57.50; H, 3.02; N, 5.59; found: C, 57.54; H, 3.06; N, 5.63 %.

15b

IR (KBr, cm-1): 3129 (O-H), 1734 (C=O), 1554 (C=N), 1544 (-C=C-), 1494 (-C=C-, aromatic), 1143 (Ar-F); 1H NMR (DMSO- d6): d 2.20 (s, 3H), 7.08- 8.35 (m, 12H, Ar-H and =CH), 8.48 (s, 1H, pyrazole proton);  MS: m/z 466 (M+); Anal. Calcd.: C, 61.74; H, 3.45; N, 6.00; found: C, 61.78; H, 3.48; N, 6.03 %.

15c

IR (KBr, cm-1): 3124 (O-H), 1739 (C=O), 1558 (C=N), 1558 (-C=C-), 1506 (-C=C-, aromatic), 1142 (Ar-F); 1H NMR (DMSO- d6): d 2.21 (s, 3H), 7.03- 8.31 (m, 12H, Ar-H and =CH), 8.47 (s, 1H, pyrazole proton);  MS: m/z 510 (M+); Anal. Calcd.: C, 56.37; H, 3.15; N, 5.48; found: C, 56.40; H, 3.18; N, 5.52 %.

15d

IR (KBr, cm-1): 3130 (O-H), 1732 (C=O), 1551 (C=N), 1549 (-C=C-), 1495 (-C=C-, aromatic), 1141 (Ar-F); 1H NMR (DMSO- d6): d 2.20 (s, 3H), 7.03- 8.37 (m, 11H, Ar-H and =CH), 8.49 (s, 1H, pyrazole proton);  MS: m/z 480 (M+); Anal. Calcd.: C, 62.43; H, 3.77; N, 5.82; found: C, 62.47; H, 3.80; N, 5.85 %.

15e

IR (KBr, cm-1): 3135 (O-H), 1739 (C=O), 1559 (C=N), 1535 (-C=C-), 1503 (-C=C-, aromatic), 1151 (Ar-F); 1H NMR (DMSO- d6): d 2.20 (s, 3H), 2.31 (s, 3H), 7.00- 8.27 (m, 12H, Ar-H and =CH), 8.42 (s, 1H, pyrazole proton);  MS: m/z 446 (M+); Anal. Calcd.: C, 67.25; H, 4.29; N, 6.27; found: C, 67.28; H, 4.33; N, 6.30 %.

(E)-5-(1-(4-Fluorophenyl)-3-(thiophen-2-yl)-1H-pyrazol-4-yl)-1-(2-hydroxyphenyl)pent-4-ene-1,3-dione 16.

Compound 15 (0.03 moles) was dissolved in 15 ml of dry pyridine. To this mixture powdered KOH (1 gm) was added and the reaction mixture was stirred on the magnetic stirrer for 3 hours. Then it was poured over crushed ice and acidified with acetic acid. The product was then separated by filtration, washed with water, dried and crystallized with acetic acid to afford 16.

Table 2– Antimicrobial activity results for concentration 1000μg/ml.

Compd

Antifungal test models

Antibacterial test models

C. albicans

 

A. fumigatus

 

A. Niger

S. aureus

 

E. coli

 

S. epidermidis

P. Vulgaris

2a 12 8 10 12 11 12
2b 10 12 10 8 10 8
2c 10 10
2d 10 8 8 12 6 12 8
2e 10 6 8 11 10 10 8
3a 8 6 8 10 11 8
3b 10 6 12 10 8 12
3c 6 8 6 8 12 6
3d 11 6 8 8 10 8 6
3e 8 6 11 8 6
4a 10 8 8 12 10 8 6
4b 10 6 4 10 10 6
4c 12 6 6 11 10 8 4
4d 10 8 10 6 6 8
4e 8 4 6 12 10 8 4
10a 8 4 10 8 8 6 8
10b 4 6 8 6 4 4
10c 8 6 4 6 8 6
10d 6 4 10 8
10e 10 6 4 6 8 9 8
10f 4 6 4 8 6 6 4
11a 8 6 6h 8h 6
11b 6 8 6 12 10 11 12
11c 11 6 8 10 6 8
11d 10 6 4 6 8 11
11e 8 4 6 8 6 6
11f 4 8 6 6 7 4
12a 11 10 8 6 4 6 8
12b 10 5 6 4 6 6 4
12c 10 6 6 12 10 6 6
12d 8 6 6 10 8 10 8
12e 10 6 6 12 8 6 12
12f 8 4 6 10 6 8 4
13a 10 6 8 10 8 6 6
13b 6 8 6 8 6 8 4
13c 8 10 10 6 8 10 6
13d 8 4 8 10 8
13e 6 8 8 10 6
13f 6 7 8 6 10 6
15a 8 8 6 10 8 6
15b 6 6 4 9 6 8
15c 8 6 10 6 4
15d 8 8 8 4 6 10
15e 8 4 4 7 8
16a 12 8 4 6 8 10 4
16b 12 10 8 6 4 6
16c 8 6 6 12 10 13
16d 10 8 6 12 10 10
16e 10 8 6 10 8 6 6
17a 10h 8 6 6h 8h 8 4
17b 12 8h 10 12h 10 8
17c 12 6 8 12 6
17d 6 4 6 7 9 6
17e 12 6 8 11 14 16
Fluconazole10µg/disc

24

14

20

NA

NA

NA

NA

Amikacin20µg/ml

NA

NA

NA

28

20

23

18

NT: Not tested, h: hazy.

16a

IR (KBr): 3094 (O-H), 1643 (C=O), 1623 (-C=C-), 1133 (Ar-F) cm-1; 1H NMR (DMSO- d6):  δ 6.17-8.03 (m, 11H, Aromatic and olefinic protons), 11.54 (s, 1H, phenolic proton), 15.21 (1H, enolic proton); MS: m/z 500 (M+); Anal. Calcd.: C, 57.50; H, 3.02; N, 5.59; found: C, 57.54; H, 3.06; N, 5.63 %.

16b

IR (KBr): 3105 (O-H), 1649 (C=O), 1620 (-C=C-), 1140 (Ar-F) cm-1; 1H NMR (DMSO- d6):  δ 6.11-8.10 (m, 12H, Aromatic and olefinic protons), 11.58 (s, 1H, phenolic proton), 15.20 (1H, enolic proton); MS: m/z 466 (M+); Anal. Calcd.: C, 61.74; H, 3.45; N, 6.00; found: C, 61.78; H, 3.49; N, 6.04 %.

16c

IR (KBr): 3087 (O-H), 1635 (C=O), 1620 (-C=C-), 1123 (Ar-F) cm-1; 1H NMR (DMSO- d6):  δ 6.12-8.06 (m, 12H, Aromatic and olefinic protons), 11.55 (s, 1H, phenolic proton), 15.19 (1H, enolic proton); MS: m/z 510 (M+); Anal. Calcd.: C, 56.37; H, 3.15; N, 5.48; found: C, 56.40; H, 3.18; N, 5.51 %.

16d

IR (KBr): 3101 (O-H), 1652 (C=O), 1626 (-C=C-), 1142 (Ar-F) cm-1; 1H NMR (DMSO- d6):  δ 2.31 (s, 3H), 6.20 -8.12 (m, 11H, Aromatic and olefinic protons), 11.49 (s, 1H, phenolic proton), 15.25 (1H, enolic proton); MS: m/z 480 (M+); Anal. Calcd.: C, 62.43; H, 3.77; N, 5.82; found: C, 62.47; H, 3.81; N, 5.86 %.

16e

IR (KBr): 3087 (O-H), 1633 (C=O), 1627 (-C=C-), 1147 (Ar-F) cm-1; 1H NMR (DMSO- d6):  δ 2.20 (s, 3H), 6.23-8.01 (m, 12H, Aromatic and olefinic protons), 11.48 (s, 1H, phenolic proton), 15.21 (1H, enolic proton); MS: m/z 446 (M+); Anal. Calcd.: C, 67.25; H, 4.29; N, 6.27; found: C, 67.28; H, 4.32; N, 6.30 %.

2-((E)-2-(1-(4-Fluorophenyl)-3-(thiophen-2-yl)-1H-pyrazol-4-yl)vinyl)-4H-chromen-4-one 17.

Compound 16 (0.01 moles) was dissolved in 15 ml glacial acetic acid in RBF. To this reaction mixture 1 ml conc. HCl was added and contents were refluxed for 2 hours. Then it was cooled and poured over crushed ice. The product was then separated by filtration, washed with water, dried and crystallized with acetic acid to afford 17.

17a

IR (KBr, cm-1): 1651 (C=O), 1559 (C=N), 1505 (C=C), 1149 (Ar-F); 1H NMR (DMSO- d6): d  6.64 (s, 1H, Ar-H), 7.01-8.52 (m, 11H, Ar-H), 9.12 (s, 1H); MS: m/z 482 (M+); Anal. Calcd.: C, 59.64; H, 2.71; N, 5.80; found: C, 57.82; H, 2.46; N, 6.17 %.

17b

IR (KBr, cm-1): 1654 (C=O), 1548 (C=N), 1509 (C=C), 1156 (Ar-F); 1H NMR (DMSO- d6): d  6.65 (s, 1H, Ar-H), 7.07-8.40 (m, 12H, Ar-H), 9.16 (s, 1H); MS: m/z 448 (M+); Anal. Calcd.: C, 64.21; H, 3.14; N, 6.24; found: C, 64.24; H, 3.17; N, 6.27 %.

17c

IR (KBr, cm-1): 1659 (C=O), 1557 (C=N), 1501 (C=C), 1152 (Ar-F); 1H NMR (DMSO- d6): d  6.63 (s, 1H, Ar-H), 7.05-8.50 (m, 12H, Ar-H), 9.13 (s, 1H); MS: m/z 500 (M+); Anal. Calcd.: C, 58.43; H, 2.86; N, 5.68; found: C, 58.46; H, 2.89; N, 5.71 %.

17d

IR (KBr, cm-1): 1653 (C=O), 1549 (C=N), 1498 (C=C), 1141 (Ar-F); 1H NMR (DMSO- d6): d  2.31 (s, 3H), 6.65 (s, 1H, Ar-H), 7.01-8.42 (m, 11H, Ar-H), 9.15 (s, 1H); MS: m/z 462 (M+); Anal. Calcd.: C, 64.86; H, 3.48; N, 6.05;  found: C, 64.90; H, 3.52; N, 6.09 %.

17e

IR (KBr, cm-1): 1658 (C=O), 1560 (C=N), 1514 (C=C), 1145 (Ar-F); 1H NMR (DMSO- d6): d  2.28 (s, 3H), 6.61 (s, 1H, Ar-H), 7.04-8.39 (m, 12H, Ar-H), 9.14 (s, 1H); MS: m/z 428 (M+); Anal. Calcd.: C, 70.08; H, 4.00; N, 6.54; found: C, 70.12; H, 4.03; N, 6.58 %.

References

  1.  Ansary, A. K.; Omar, H. A. Bull. Faculty Pharm. 2001, 39, 17.
  2. Kavitha, P. N.; Vijayanthimala, P.; Saravanan, J.; Mohan, S. Res. J. Pharma., Bio. and Chem. Sci. 2010, 1(2), 124-130.
  3. Jose, L.; Gonzalez, C. E.; Stephens, T.; Wenzler, R. Eur. J. Med. Chem. 2007, 42, 552-557.
  4. Folkes, A. J.; Ahmadi, K.; Alderton, W. K.; Alix, S.; Baker, S. J. Journal of  Medi. Chem. 2008, 51, 5522-5532.
  5. Kulandasamy, R.; Adhikari, A. V.; Stables, J. P. Eur. J. Med. Chem. 2009, 44(11), 4376-4384.
  6. Oganesyan, E. T.;  Saraf, A. S.; Ivchenko, A. V. Pharma. Chem. Jour. 1993, 27(1), 52-54.
  7. Bhatnagar, S.; Sahi, S.;   Kackar, P.;  Kaushik, S.; Dave, M. K.; Shukla, A.;  Goel, A. Bioorg. Med. Chem. Lett. 2010,  20(16), 4945–4950.
  8. Pawar, S. P.;  Kondhare, D. D.;  Zubaidha, P. K. Med. Chem. Res. 2013, 22 (2), 753-         757.
  9. Gomes, A.;  Fernandes, E.;  Silva, A. M. S.;  Pinto, D. C. G. A.; Santos, C. M. M.;  Cavaleiro, J. A.S.; Lima, J. L. F. C.  Biochem. Pharmaco. 2009, 78(2), 171–177.
  10. Momin, M.; Ramjugernath, D.; Chenia, H.; Koorbanally, N. A.  Journal of Chemistry 2013, Article ID 436758.
  11. Ono, M.; Maya, Y.; Haratake, M.; Nakayama, M. Bioorg. Med. Chem. 2007, 15, 444–450.
  12. Karale, B. K.;  Pawar, P. Y.; Gadakh, A. V.; Akolkar, H. N.; Rindhe, S. S. Ind. Jour. Het. Chem. 2014,  23(3), 283-292.
  13. Peng-Cheng, Lv.; Hai-L, Z., Huan-Qiu, Li; Sun, J; Zhou, Y. Bioorg. Med. Chem. 2010, 18, 4606–4614.
  14. Bonesi, M; Loizzo, M. R.; Statti, G. A.; Michel, S.; Menichini, T. F. Bioorg. Med. Chem. Lett. 2010, 20, 1990–1993.
  15. Zhang, K.; Wang, P.;  Xuan, L. N.;  Fu, X. Y.;  Jing, F.; Li, S.;  Liu, Y. M.; Chen,   B. Q.  Bioorg. Med. Chem. Lett. 2014, 24 (22), 5154-5156.
  16. Jain, S. K.; Mishra, P. Eur. J. Exp. Bio. 2014, 4(2), 337-341.
  17. Wu, J.;  Li, J.; Xu, M. H.;  Liu, D. Bioorg. Med. Chem. Lett. 2014, 24(14), 3050-3056.
  18. Samel, A. B.; Pai, N. R. J. Chin. Chemi. Soc. 2010, 57, 1327-1330.
  19. Gadhave, A. G.; Gaikar, R. B.; Kuchekar, S. R.; Karale, B. K. Journal of   Heterocyclic Chemistry 2014, 51(6), 1849–1855.
  20. Bhalgat, C. M.; Ali, M. I.; Ramesh, B.; Ramu, G. Arabian Journal of Chemistry     2014, 7, 986–993.
  21. Al-Soud, Y. A.;  Heydel, M.; Hartmann, R. W. Tetrahedron Letters 2011, 52(48), 6372–6375.
  22. Tarzia, G.; Ocelli, E.; Toja, E.; Barone, D.; Corsico, N.; Gallico, L.; Luzzani, F. J. Med. Chem. 1988, 31(6), 1115-1123.
  23. Winter, E.; Lecerf-Schmidt, F.; Gozzi, G.; Peres, B.; Lightbody, M.; Gauthier, C.; Ozvegy-Laczka, C.; Szakacs, G.; Sarkadi, B.; Creczynski-Pasa, T. B.; Boumendjel, A.; Di Pietro, A. J. Med. Chem. 2013, 56(24), 9849-9860.
  24. Gaspar, A.; Silva, T.;  Anez, M. Y.; Vina, D.; Orallo, F.; Ortuso, F.; Uriarte, E.; Alcaro, S.; Borges, F. J. Med. Chem. 2011, 54(14), 5165-5173.
  25. Andrews, S. P.;  Mason, J. S.; Hurrell, E.; Congreve, M. Hide Affiliations Heptares Therapeutics Ltd., Biopark, Broadwater Road, Welwyn Garden City, UK  E-mail: steve.andrews@heptares.com Med. Chem. Commun.  2014, 5, 571-575.
  26. Kang, W.; Du, X.; Wang, L.; Hu, L.; Dong, Y.; Bian, Y.;  Li, Y. Chin.       J. Chem. 2013, 31(10), 1305–1314.
  27. Garg, N.;  Chandra, T.; Archana; Jain, A. B.;  Kumar, A. Eur. J. Med. Chem. 2010, 45(4), 1529–1535.
  28. Ameta, K. L.; Rathore N. S.; Kumar, B. J. Serb. Chem. Soc. 2012, 77(6), 725–      731.
  29. Ayral, E.; Gloanec, P.; Berge, G.; de Nanteuil, G.; Mennecier, P.; Rupin, A.; Verbeuren, T. J.; Fulcrand, P.; Martinez, J.; Hernandez, J. F. Bioorg. Med. Chem. Lett. 2009, 19(5), 1386-1391.
  30. Tran, P. V.; Bymaster, F. P.; McNamara, R. K.; Potter, W. Z. J. Clin. Psychopharmacol. 2003, 23(1), 78-86.
  31. Sauzem, P. D.; Machado, P. M.; Rubin, A.; Sant’Anna, G. S.; Faber, H. B.; De      Souza, A. H.;  Mello, C. F.;  Beck, P.;  Burrow, R. A.; Bonacorso, H. G.; Zanatta, N.; Martins, M. A. P. Eur. J. Med. Chem. 2008, 43(6), 1237-1247.
  32. Cunico, W.; Cechinel, C. A.; Bonacorso, H. G.; Martins, M. A. P.; Zanatta, N.; De Souza, M. V.   N.; Freitas, I. O.; Soares, R. P. P.; Krettli, A. U. Bioorg. Med.    Chem. Lett. 2006, 16(3), 649-653.
  33. Ali, M. A.; Shaharyar,  M. and Siddiqui, A. A., Eur. J. Med. Chem. 2007, 42(2), 268-275.
  34. Johnson, M.; Younglove, B.; Lee, L.; LeBlanc, R.; Holt, H.; Jr Hills, P.; Mackay, H.; Brown, T.; Mooberry, S. L.; Lee, M. Bioorg. Med. Chem. Lett. 2007, 17(21), 5897-5901.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.